Randomized Controlled Trial: Ketamine for Rapid Reduction of Symptoms of Depression and Suicidality

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study – American Journal of Psychiatry (link to abstract – $ for full-text)

Commentaries: Intranasal Esketamine Found Effective in Rapid Reduction of Depression, Suicidal Thoughts – Psychiatric News Alert (free) AND Fast-acting benefits of ketamine for depression and suicidality – American Psychiatric Association, via ScienceDaily (free) AND Ketamine ‘shows promise’ in treating depression – OnMedica (free) AND Ketamine Spray Effective for Suicidality, but Abuse Concerns Linger – Medscape (free registration required)

Related: ‘Cautious Optimism’ Marks Outlook for Ketamine, Mood Disorders – Psychiatric News (free)